Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans
US FDA rescinds breakthrough designations for Tonix’ PTSD therapy Tonyma and Trevena’s novel pain drug Olinvo after clinical trial disappointments – and after identifying other regulatory pathways to market.
You may also be interested in...
Sixteen applications are in line for US FDA decisions in August. Ten are novel agents.
Keeping Track: Good News For Deciphera, BMS And Clovis; Bad News For bluebird/BMS, Blueprint And Tonix
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
The latest drug development news and highlights from our US FDA Performance Tracker.